HALO – halozyme therapeutics, inc. (US:NASDAQ)

News

Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $68.00 price target on the stock.
How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% [Yahoo! Finance]
Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? [Yahoo! Finance]
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock [Yahoo! Finance]
Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com